Janus Living (NYSE:JAN – Get Free Report) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.970-0.990 for the period, compared to the consensus earnings per share estimate of 0.970.
Janus Living Stock Down 0.2%
NYSE:JAN opened at $28.46 on Tuesday. The firm’s 50 day moving average is $29.64 and its 200 day moving average is $28.02. Janus Living has a 12 month low of $22.76 and a 12 month high of $32.83.
Janus Living (NYSE:JAN – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The REIT reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The firm had revenue of $216.46 million during the quarter, compared to analysts’ expectations of $203.32 million. The business’s revenue was up 45.4% on a year-over-year basis. As a group, equities research analysts anticipate that Janus Living will post 0.97 earnings per share for the current year.
Janus Living Announces Dividend
The company also recently disclosed a monthly dividend, which will be paid on Tuesday, December 29th. Investors of record on Friday, December 18th will be issued a $0.0475 dividend. The ex-dividend date of this dividend is Friday, December 18th. This represents a $0.57 annualized dividend and a yield of 2.0%.
Wall Street Analyst Weigh In
JAN has been the topic of several recent research reports. Zacks Research downgraded shares of Janus Living from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 20th. Compass Point began coverage on shares of Janus Living in a research note on Wednesday, September 16th. They issued a “neutral” rating and a $37.00 target price for the company. Royal Bank Of Canada lifted their target price on shares of Janus Living from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Monday, August 10th. Wall Street Zen raised shares of Janus Living from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald upped their price target on shares of Janus Living from $30.00 to $34.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Janus Living presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.35.
Check Out Our Latest Analysis on JAN
Key Stories Impacting Janus Living
Here are the key news stories impacting Janus Living this week:
- Positive Sentiment: Janus Living reported third-quarter adjusted FFO of $0.25 per share, narrowly exceeding the $0.24 analyst consensus. Revenue rose 78.3% year over year to $268.3 million, while adjusted FFO increased 46%. Janus Living Reports Third Quarter 2026 Results and Increases Full Year 2026 Guidance
- Positive Sentiment: The senior-housing REIT increased its full-year 2026 guidance, signaling management expects continued operating momentum. Janus Living Reports Third Quarter 2026 Results and Increases Full Year 2026 Guidance
- Positive Sentiment: Mizuho initiated coverage with an “outperform” rating and a $33 price target, implying approximately 15.9% upside from the referenced price. The new coverage may improve investor visibility and institutional interest. Mizuho initiates coverage of Janus Living at outperform
- Negative Sentiment: Despite the operating beat, Janus Living posted a GAAP net loss of $0.02 per share. Acquisition-related depreciation and amortization reduced reported earnings, creating a potential valuation concern even though adjusted FFO was positive. Janus Living Q3 2026 Revenue Beat as Acquisition Depreciation Drives GAAP Loss
Janus Living Company Profile
Further Reading
- Five stocks we like better than Janus Living
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
Receive News & Ratings for Janus Living Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janus Living and related companies with MarketBeat.com's FREE daily email newsletter.
